Differential effects of phorbol esters on proliferation and calcyclin expression in human endometrial carcinoma cells.
Calcyclin is a member of the S-100 family of calcium-binding proteins, whose expression is enhanced when quiescent cells are exposed to mitogenic signals. The function of calcyclin is unknown, but it is thought to be involved in modulating the intracellular calcium concentration following mitogenic stimuli. Since activation of protein kinase C (PKC) also occurs following stimulation of quiescent cells by a variety of mitogens, we have investigated the relationship between calcyclin expression and PKC activation in three human endometrial adenocarcinoma cell lines. The addition of 10(-7) M 4 beta-phorbol 12-myristate 13-acetate (PMA) to HEC-50 and HEC-1B cell cultures resulted in a change in cell morphology, an inhibition of proliferation, an increase in calcyclin transcription rate, and an increase in calcyclin mRNA and calcyclin protein levels. In contrast, PMA had no effect on cell morphology or cell proliferation in the Ishikawa adenocarcinoma cell line but enhanced calcyclin expression. Another bioactive phorbol ester had the same effect, whereas the calcium ionophore A23187 and the non-phorbol-ester-type tumor promoter thapsigargin had no effect on calcyclin expression. The effect of PMA on calcyclin expression was blocked by the simultaneous addition of the PKC inhibitor staurosporine and by protein synthesis inhibition with cycloheximide. RNase protection assays and primer extension analysis demonstrated that PMA enhanced transcription from all three of the previously identified transcription start sites in the calcyclin gene. These data clearly demonstrate a dissociation between calcyclin expression and cellular proliferation and suggest that the enhanced calcyclin expression which is seen in quiescent cells following mitogenic stimuli may result from activation of the PKC system.
Gong
Y
Y
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Alkhalaf
B
B
Murphy
L J
LJ
Murphy
L C
LC
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000470:Alkaloids / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D018797:Cell Cycle Proteins; D002455:Cell Division / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D015240:Phorbol 12,13-Dibutyrate / Q000494:pharmacology*; D010703:Phorbol Esters / Q000494:pharmacology*; D011493:Protein Kinase C / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; D015398:Signal Transduction; D019311:Staurosporine; D013729:Terpenes / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D019284:Thapsigargin; D014594:Uterine Neoplasms / Q000378:metabolism* / Q000473:pathology
D000470:Alkaloids; D002135:Calcium-Binding Proteins; D018797:Cell Cycle Proteins; D009363:Neoplasm Proteins; D010703:Phorbol Esters; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; D013729:Terpenes; C055351:S100A6 protein, human; C008876:phorbol-12,13-didecanoate; D015240:Phorbol 12,13-Dibutyrate; D000001:Calcimycin; D019284:Thapsigargin; D003513:Cycloheximide; D011493:Protein Kinase C; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate